Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA3 | P07451 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127246 | 0.82 | F2 (0.57) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL9057442 | 0.82 | F2 (0.63) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL663730 | 0.82 | CYP2C19 (0.59) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL10073006 | 0.80 | F2 (0.55) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL7777272 | 0.80 | F2 (0.55) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL2412814 | 0.80 | F2 (0.55) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL14382173 | 0.80 | F2 (0.55) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL2412815 | 0.80 | F2 (0.55) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL7770967 | 0.80 | F2 (0.55) | F2PRSS1PRSS2PRSS3GAA | |
| SCHEMBL1162226 | 0.78 | HTT (0.55) | F2PRSS1PRSS2PRSS3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006023720-A2 | REACTIONS OF ENOLIZABLE A-AMINO ALDEHYDES OR KETONES TO FORM AMINE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-03-02 | — | — | WO | claimed |
| US-6562840-B1 | Non-peptidic inhibitors of proteolytic enzymes such as urokinase | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | claimed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | claimed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | claimed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | claimed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |
| US-4837307-A | [1,1'-biphenyl]compounds having a 2,2'-(alkyl)bridge and a 3-yl(substituted)methyl substituent | FMC CORPORATION (US) | 1989-06-06 | — | — | US | claimed |
| US-4668792-A | Intermediates to insecticidal [1,1'-biphenyl]-3-ylmethyl esters | FMC CORPORATION (US) | 1987-05-26 | — | — | US | claimed |
| EP-1658298-B1 | PHOSPHORUS-CONTAINING IMIDAZOLINES AND METAL COMPLEXES THEREOF | SOLVIAS AG (CH) | 2008-03-26 | — | — | EP | disclosed |
| US-20070010493-A1 | Phospinite-imidazolines and metal complexes thereof | SOLVIAS AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1658298-A2 | NOVEL ORGANIC COMPOUNDS AND METAL COMPLEXES | Solvias AG (CH) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005021562-A2 | PHOSPINITE-IMIDAZOLINES AND METAL COMPLEXES THEREOF | SOLVIAS AG (CH) | 2005-03-10 | — | — | WO | disclosed |
| US-6562840-B1 | Non-peptidic inhibitors of proteolytic enzymes such as urokinase | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-6515002-B2 | 4-(4-(1-phenyl-5-propylpyrazol4-yl)(1,3-thiazol-2-yl))-5 -methylthiothiophene-2-carboxamidine, for example; complement inhibitors; treating tissue damage, inflammation, or autoimmune diseases | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | disclosed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000047194-A9 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | DIMENSIONAL PHARM INC (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-2000047194-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| US-4837307-A | [1,1'-biphenyl]compounds having a 2,2'-(alkyl)bridge and a 3-yl(substituted)methyl substituent | FMC CORPORATION (US) | 1989-06-06 | — | — | US | disclosed |
| US-4668792-A | Intermediates to insecticidal [1,1'-biphenyl]-3-ylmethyl esters | FMC CORPORATION (US) | 1987-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010493-A1 | Phospinite-imidazolines and metal complexes thereof | H1-0, H1-2, H1-3 | F2 36/4885PRSS1 3725/4885PRSS2 3760/4885 |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | F2 92/4885PRSS1 5/4885PRSS2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.